PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Pollack, Charles V.
TI  - RE-VERSE AD
DP  - 2015 Sep 10
TA  - MD Conference Express
PG  - 4--5
VI  - 15
IP  - 21
4099  - http://mdc.sagepub.com/content/15/21/4.short
4100  - http://mdc.sagepub.com/content/15/21/4.full
AB  - In the open-label, phase 3 RE-VERSE AD trial, idarucizumab resulted in complete reversal of dabigatran-related anticoagulation in up to 88% of patients with uncontrolled bleeding or who required an emergent procedure, with no safety concerns. The median maximum reversal of 100% occurred within 4 hours and was evident within minutes after the first of 2 idarucizumab infusions.